AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study
Portfolio Pulse from Vandana Singh
AstraZeneca Plc (NASDAQ:AZN) announced positive results from the EMERALD-1 Phase 3 trial of Imfinzi in combination with TACE and bevacizumab for unresectable hepatocellular carcinoma (HCC). The trial showed a significant improvement in progression-free survival (PFS) compared to TACE alone. The data will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The safety profile was consistent with the known profiles of the medicines. AZN shares saw a slight increase of 0.06% to $66.56.
January 19, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Imfinzi, combined with TACE and bevacizumab, showed improved PFS in liver cancer study, which could enhance the drug's market potential and bolster investor confidence.
The positive trial results for Imfinzi in treating HCC are likely to be seen as a strong indicator of the drug's efficacy and potential for increased sales, which could positively impact AstraZeneca's stock price in the short term. The slight increase in share price on the announcement day reflects initial positive investor reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100